ABBOTT LABORATORIES
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
ABT$109.93-3.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Comprehensive Income
| Year Ended December 31 | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net Earnings | $6,524 | $13,402 | $5,723 |
| Foreign currency translation gain (loss) adjustments, net of taxes of $62 in 2025 and $— in 2024 and 2023 | 1,574 | (1,001) | 229 |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $149 in 2025, $228 in 2024, and $31 in 2023 | 610 | 765 | 117 |
| Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $(60) in 2025, $48 in 2024, and $(66) in 2023 | (279) | 169 | (134) |
| Other Comprehensive Income (Loss) | 1,905 | (67) | 212 |
| Comprehensive Income | $8,429 | $13,335 | $5,935 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | $(5,931) | $(7,505) | $(6,504) |
| Net actuarial (losses) and prior service (cost) and credits | (1) | (611) | (1,376) |
| Cumulative gains (losses) on derivative instruments designated as cash flow hedges | (69) | 210 | 41 |
| Accumulated other comprehensive income (loss) | $(6,001) | $(7,906) | $(7,839) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.